Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 509

1.

Patient-reported Outcomes of Blue Light Flexible Cystoscopy with Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: Results from a Prospective Multi-center Study.

Smith A, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Lotan Y; Flexible Blue Light Study Group Collaborators.

BJU Int. 2018 Jul 6. doi: 10.1111/bju.14481. [Epub ahead of print]

PMID:
29979488
2.

Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.

Williams SB, Shan Y, Jazzar U, Mehta HB, Baillargeon JG, Huo J, Senagore AJ, Orihuela E, Tyler DS, Swanson TA, Kamat AM.

JAMA Surg. 2018 Jun 27. doi: 10.1001/jamasurg.2018.1680. [Epub ahead of print]

PMID:
29955780
3.

CSF protein concentration associated with ventriculoperitoneal shunt obstruction in tuberculous meningitis.

Kamat AS, Gretschel A, Vlok AJ, Solomons R.

Int J Tuberc Lung Dis. 2018 Jul 1;22(7):788-792. doi: 10.5588/ijtld.17.0008.

PMID:
29914605
4.

Salvage topical therapy for upper tract urothelial carcinoma.

Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

World J Urol. 2018 May 26. doi: 10.1007/s00345-018-2349-9. [Epub ahead of print]

PMID:
29804202
5.

Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases.

Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC.

Hum Pathol. 2018 May 12. pii: S0046-8177(18)30162-X. doi: 10.1016/j.humpath.2018.05.005. [Epub ahead of print]

PMID:
29763719
6.

Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy.

Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM.

Clin Genitourin Cancer. 2018 Mar 27. pii: S1558-7673(18)30211-8. doi: 10.1016/j.clgc.2018.03.002. [Epub ahead of print]

7.

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

Li R, Spiess PE, Kamat AM.

Eur Urol. 2018 Apr 20. pii: S0302-2838(18)30279-3. doi: 10.1016/j.eururo.2018.04.012. [Epub ahead of print]

PMID:
29685644
8.

Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.

Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB.

Cancer. 2018 Apr 16. doi: 10.1002/cncr.31404. [Epub ahead of print]

PMID:
29660813
9.

Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.

Tabayoyong W, Li R, Gao J, Kamat A.

Urol Clin North Am. 2018 May;45(2):155-167. doi: 10.1016/j.ucl.2017.12.002. Epub 2018 Feb 21. Review.

PMID:
29650132
10.

An observational study on glabellar wrinkle patterns in Indians.

Kamat A, Quadros T.

Indian J Dermatol Venereol Leprol. 2018 Apr 4. doi: 10.4103/ijdvl.IJDVL_211_17. [Epub ahead of print]

11.

Impact of oral health-related behaviors on dental caries among children with special health-care needs in Goa: A cross-sectional study.

Gadiyar A, Gaunkar R, Kamat AK, Tiwari A, Kumar A.

J Indian Soc Pedod Prev Dent. 2018 Jan-Mar;36(1):33-37. doi: 10.4103/JISPPD.JISPPD_214_17.

12.

Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.

Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB.

BJU Int. 2018 Jul;122(1):89-98. doi: 10.1111/bju.14211. Epub 2018 Apr 23.

PMID:
29569824
13.

Role of proton balance in formation of self-assembled chitosan nanoparticles.

Dey A, Kamat A, Nayak S, Danino D, Kesselman E, Dandekar P, Jain R.

Colloids Surf B Biointerfaces. 2018 Jun 1;166:127-134. doi: 10.1016/j.colsurfb.2018.03.017. Epub 2018 Mar 14.

PMID:
29558703
14.

Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy.

Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS.

Surg Innov. 2018 Jun;25(3):242-250. doi: 10.1177/1553350618764218. Epub 2018 Mar 20.

PMID:
29557251
15.

Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ.

Urol Oncol. 2018 Mar 13. pii: S1078-1439(17)30591-4. doi: 10.1016/j.urolonc.2017.11.006. [Epub ahead of print] No abstract available.

PMID:
29548621
16.

Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.

Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, Shariat SF, Sylvester RJ, Gontero P.

Eur Urol. 2018 Jun;73(6):925-933. doi: 10.1016/j.eururo.2018.02.014. Epub 2018 Mar 6. Review.

PMID:
29523366
17.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Feb 26. pii: S1078-1439(18)30036-X. doi: 10.1016/j.urolonc.2018.01.014. [Epub ahead of print] Review.

PMID:
29496372
18.

Alternative splicing variant of the scaffold protein APPL1 suppresses hepatic adiponectin signaling and function.

Galan-Davila AK, Ryu J, Dong K, Xiao Y, Dai Z, Zhang D, Li Z, Dick AM, Liu KD, Kamat A, Lu M, Dong Q, Liu F, Dong LQ.

J Biol Chem. 2018 Apr 20;293(16):6064-6074. doi: 10.1074/jbc.RA118.002162. Epub 2018 Feb 26.

PMID:
29483192
19.

DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease.

Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, Xu MJ, Rui X, Han J, Jiang B, Lee D, Li N, Keyhani-Nejad F, Fan JG, Liu F, Kamat A, Musi N, Guarente L, Pacher P, Gao B, Zang M.

Hepatology. 2018 Feb 19. doi: 10.1002/hep.29849. [Epub ahead of print]

PMID:
29457836
20.

Assessment of readiness to quit tobacco among patients with oral potentially malignant disorders using transtheoretical model.

Kumar A, Tiwari A, Gadiyar A, Gaunkar RB, Kamat AK.

J Educ Health Promot. 2018 Jan 10;7:9. doi: 10.4103/jehp.jehp_75_17. eCollection 2018.

21.

Contribution of bladder cancer pathology assessment in planning clinical trials.

Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM.

Urol Oncol. 2018 Jan 29. pii: S1078-1439(18)30001-2. doi: 10.1016/j.urolonc.2018.01.001. [Epub ahead of print] Review.

PMID:
29395955
22.
23.

Retraction: Thoracic Vertebral Actinomycosis Secondary to a Pulmonary Origin.

Thango NS, Kamat A, Ben Husein M, Welsh D.

Cureus. 2018 Jan 22;10(1):r10. doi: 10.7759/cureus.r10.

24.

Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.

Agarwal MB, Bhurani D, Shah C, Sood N, Singhal M, Kamat A, Chezhian S, Mishra S, Nagrale D.

Indian J Med Paediatr Oncol. 2017 Oct-Dec;38(4):508-515. doi: 10.4103/ijmpo.ijmpo_43_17.

25.

Altered expression of hepatic β-adrenergic receptors in aging rats: implications for age-related metabolic dysfunction in liver.

Shi Y, Shu ZJ, Wang H, Barnes JL, Yeh CK, Ghosh PM, Katz MS, Kamat A.

Am J Physiol Regul Integr Comp Physiol. 2018 Apr 1;314(4):R574-R583. doi: 10.1152/ajpregu.00372.2017. Epub 2017 Dec 6.

PMID:
29212811
26.

Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.

Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS; Flexible Blue Light Study Group Collaborators.

J Urol. 2018 May;199(5):1158-1165. doi: 10.1016/j.juro.2017.11.096. Epub 2017 Dec 2.

PMID:
29203268
27.

Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype.

Asur RS, Kimble DC, Lach FP, Jung M, Donovan FX, Kamat A, Noonan RJ, Thomas JW, Park M, Chines P, Vlachos A, Auerbach AD, Smogorzewska A, Chandrasekharappa SC.

Mol Genet Genomic Med. 2018 Jan;6(1):77-91. doi: 10.1002/mgg3.350. Epub 2017 Nov 30.

28.

Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin.

Williams SB, Kamat AM, Mmeje C, Ye Y, Huang M, Chang DW, Dinney CP, Wu X.

Oncotarget. 2017 Sep 23;8(51):88782-88791. doi: 10.18632/oncotarget.21222. eCollection 2017 Oct 24.

29.

Secondary Tumors After Urinary Diversion.

Li R, Baack Kukreja JE, Kamat AM.

Urol Clin North Am. 2018 Feb;45(1):91-99. doi: 10.1016/j.ucl.2017.09.010. Review.

PMID:
29169454
30.

It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis.

Ferguson JE 3rd, Kamat AM.

Urol Oncol. 2018 Feb;36(2):39-42. doi: 10.1016/j.urolonc.2017.10.019. Epub 2017 Nov 20.

PMID:
29158136
31.

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG.

Urol Oncol. 2017 Nov 8. pii: S1078-1439(17)30551-3. doi: 10.1016/j.urolonc.2017.10.014. [Epub ahead of print] Review.

PMID:
29128420
32.

The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.

Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF.

Eur Urol. 2018 Apr;73(4):543-557. doi: 10.1016/j.eururo.2017.09.030. Epub 2017 Nov 7. Review.

PMID:
29122377
33.

A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families.

Kimble DC, Lach FP, Gregg SQ, Donovan FX, Flynn EK, Kamat A, Young A, Vemulapalli M, Thomas JW, Mullikin JC, Auerbach AD, Smogorzewska A, Chandrasekharappa SC.

Hum Mutat. 2018 Feb;39(2):237-254. doi: 10.1002/humu.23366. Epub 2017 Nov 22.

PMID:
29098742
34.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA.

Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18. Review.

PMID:
29055653
35.

Should we care more about SPARE?

Lee EK, Kamat AM.

BJU Int. 2017 Nov;120(5):605-606. doi: 10.1111/bju.13953. No abstract available.

PMID:
29035018
36.

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE.

J Immunother Cancer. 2017 Sep 28;5(1):80. doi: 10.1186/s40425-017-0280-z. No abstract available.

37.

Effects of thiazolidinedione in patients with active bladder cancer.

Li R, Metcalfe MJ, Ferguson JE 3rd, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM.

BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23.

PMID:
28872778
38.

The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells.

Jinesh GG, Kamat AM.

Cancer Res. 2017 Nov 15;77(22):6144-6156. doi: 10.1158/0008-5472.CAN-17-0522. Epub 2017 Aug 30.

PMID:
28855211
39.

Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.

Jinesh GG, Manyam GC, Mmeje CO, Baggerly KA, Kamat AM.

Sci Rep. 2017 Aug 29;7(1):9602. doi: 10.1038/s41598-017-08796-z.

40.

Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.

Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, Kim SP, Orihuela E, Tyler DS, Freedland SJ, Kamat AM.

Urology. 2017 Dec;110:76-83. doi: 10.1016/j.urology.2017.08.024. Epub 2017 Aug 25.

PMID:
28847688
41.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23.

PMID:
28834453
42.

Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.

Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB.

Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30215-X. doi: 10.1016/j.clgc.2017.07.018. [Epub ahead of print]

PMID:
28826932
43.

Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium.

Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C, DeGraff D, Liao JC, Taylor JA 3rd.

Bladder Cancer. 2017 Jul 27;3(3):211-223. doi: 10.3233/BLC-170111.

44.

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease.

Li R, Sylvester R, Dinney CP, Kamat AM.

Bladder Cancer. 2017 Jul 27;3(3):147-148. doi: 10.3233/BLC-179020. No abstract available.

45.

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.

Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ.

Bladder Cancer. 2017 Jul 27;3(3):145-146. doi: 10.3233/BLC-170118. No abstract available.

46.

High-grade neuroendocrine carcinoma of the urachus-report of 3 cases.

Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC.

Hum Pathol. 2017 Sep;67:126-133. doi: 10.1016/j.humpath.2017.08.003. Epub 2017 Aug 18.

PMID:
28823575
47.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE.

J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0. Erratum in: J Immunother Cancer. 2017 Sep 28;5(1):80.

48.

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Oncol Pract. 2017 Sep;13(9):621-625. doi: 10.1200/JOP.2017.024919. Epub 2017 Aug 10. No abstract available.

PMID:
28796558
49.

Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.

Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB.

Eur Urol Focus. 2017 Jan 18. pii: S2405-4569(16)30181-X. doi: 10.1016/j.euf.2016.12.005. [Epub ahead of print]

PMID:
28753837
50.

Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C.

Eur Urol Focus. 2017 Dec;3(6):577-583. doi: 10.1016/j.euf.2017.06.004. Epub 2017 Jul 13.

PMID:
28753816

Supplemental Content

Support Center